Dr. Hubbard is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
200 1st Street SW
Rochester, MN 55905- Is this information wrong?
Summary
- Dr. Joleen Hubbard is an Associate Professor of Medical Oncology at Mayo Clinic, Rochester MN. She completed medical school and residency at the University of Minnesota and hematology/oncology fellowship at Mayo Clinic, Rochester MN. Dr. Hubbard specializes in the treatment of gastrointestinal cancers, focusing on colorectal cancer, which is her area of clinical research. Dr. Hubbard is the PI of multiple phase I, II, and III clinical trials investigating novel agents for gastrointestinal cancers. Her research interests also include geriatric oncology with a special interest in clinical and biologic markers of frailty.
Dr. Hubbard is a member of the National Comprehensive Cancer Network Colon/Rectal/Anal Cancers and Senior Adult Oncology Panels. She serves as a member of the Cancer in the Gastrointestinal Cancers, Older Adult, Health Reported Outcomes, and Translational Research committees for the North American Alliance of Clinical Trials in Oncology Network. She is also a member of the Gastrointestinal Cancer Committee for the Academic and Community Cancer Research United trials network. Dr. Hubbard is program director for the Gastrointestinal Cancer Advanced Fellowship and the Vice-chair for the Division of Medical Oncology at Mayo Clinic Rochester, MN.
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2007 - 2010
University of MinnesotaResidency, Internal Medicine, 2003 - 2006- University of Minnesota Medical SchoolClass of 2003
Certifications & Licensure
MN State Medical License 2006 - 2024- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors Start of enrollment: 2011 Feb 01
- A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer Start of enrollment: 2012 Mar 01
- A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer Start of enrollment: 2014 Jan 01
- Join now to see all
Publications & Presentations
PubMed
- Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort.Emiloju, O., Yin, J., Koubek, E., Reid, J., Borad, M., Lou, Y., Seetharam, M., Edelman, M., Sausville, E., Jiang, Y., Kaseb, A., Posey, J., Davis, S., Gores, G., Rober...> ;Investigational New Drugs. 2024 Feb 1
- Plasma Assay of Cell-Free Methylated DNA Markers of Colorectal Cancer: A Tumor-Agnostic Approach to Monitor Recurrence and Response to Anticancer Therapies.Taylor, W., Mahoney, D., Then, S., Berger, C., Burger, K., Gonser, A., Doering, K., Foote, P., Kaiser, M., Allawi, H., Zhu, M., Xie, H., Hubbard, J., Kisiel, J.> ;Cancers. 2023 Dec 9
- Selecting Optimal First-Line Treatment for Microsatellite Stable and Non-Mutated RAS/BRAF Metastatic Colorectal Cancer.Oluwadunni E Emiloju, Mojun Zhu, Hao Xie, Zhaohui Jin, Frank A Sinicrope, Joleen M Hubbard> ;Current Treatment Options in Oncology. 2023 Dec 1
- Join now to see all
Lectures
- A phase I study of PolyPEPI1018 vaccine plus maintenance therapy in patients with metastatic colorectal cancer with a predictive biomarker (OBERTO).2019 ASCO Annual Meeting - 6/1/2019
- Phase I trial of TAS-102 and concurrent radiation therapy for patients with locally recurrent, unresectable or metastatic, rectal cancer.2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
- MSCO Fellows Dinner MeetingMinnesota Society of Clinical Oncology (MSCO), Minneapolis, Minnesota - 7/20/2013
Press Mentions
Can You Get Two Cancers at the Same Time?October 7th, 2022- Treos Bio, Roche Partner on Colorectal Cancer Combination TrialJuly 7th, 2021
- Treos Bio Reports Positive Final Results of Phase I/II Off-the-Shelf CRC Cancer Immunotherapy in 2020 ASCO Poster PresentationMay 29th, 2020
- Join now to see all
Hospital Affiliations
Mayo Clinic Hospital - RochesterRochester, Minnesota
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
